Liraglutide (Saxenda and Victoza): What the Research Actually Shows

What is liraglutide?

Liraglutide was the drug that proved a gut hormone analog could produce clinically meaningful weight loss in people without diabetes. Everything that followed — semaglutide, tirzepatide, retatrutide — is built on that proof.

Chemically, liraglutide is a modified copy of human glucagon-like peptide-1. Native GLP-1 is released from intestinal L-cells after eating and destroyed by the enzyme DPP-4 within minutes, which makes the natural hormone useless as a drug. Novo Nordisk fixed that by swapping one amino acid and attaching a 16-carbon fatty acid chain via a glutamic acid spacer. The fatty acid binds reversibly to albumin, shielding the molecule from enzymatic breakdown and slowing absorption from the injection site. The result is a half-life of roughly 13 hours — long enough for once-daily dosing, short enough that the drug clears within days of the last injection.

Two brands carry the same molecule. Victoza launched in 2010 for type 2 diabetes at lower strengths. Saxenda arrived in December 2014 at a higher 3.0 mg strength specifically for chronic weight management. Both are pens, both are subcutaneous, both are prescription-only. They are not interchangeable, because the licensed maximum strength and the approved indication differ.

Liraglutide sits at the older end of the GLP-1 receptor agonist class. It is not a research peptide, not a gray-market compound, and not something with a thin evidence base. It has more than fifteen years of regulatory and post-marketing history behind it.

How does liraglutide work?

Liraglutide binds the GLP-1 receptor, which is expressed on pancreatic beta cells, on gastric smooth muscle, and on neurons in the hypothalamus and brainstem. Activation produces several effects at once, described in detail in reviews of GLP-1 physiology:

• Glucose-dependent insulin release. Beta cells secrete more insulin when blood glucose is elevated, and stop when it is not — which is why GLP-1 agonists rarely cause hypoglycemia on their own.
• Glucagon suppression. Less hepatic glucose output after meals.
• Slowed gastric emptying. Food leaves the stomach more slowly, which blunts post-meal glucose spikes and prolongs fullness. This is also the main source of the nausea.
• Central appetite suppression. Signaling in the arcuate nucleus and area postrema reduces hunger and food reward. This is the dominant mechanism behind the weight loss.

The problem liraglutide solved — keeping a peptide in circulation long enough to be a drug — is the same one every later GLP-1 had to solve with different chemistry. Semaglutide uses a longer C18 diacid chain and further substitutions to reach a half-life of about a week. Comparative pharmacology across the class is reviewed in work on GLP-1 receptor agonist efficiency.

Does liraglutide actually work for weight loss?

Yes, with a caveat: it works, but modestly by 2026 standards.

The pivotal evidence is the SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015. It randomized 3,731 adults with a BMI of at least 30, or at least 27 with a weight-related comorbidity, to liraglutide 3.0 mg daily or placebo alongside lifestyle counseling. At 56 weeks, mean body weight fell 8.0% with liraglutide versus 2.6% with placebo. About 63% of the treated group lost at least 5% of body weight and 33% lost at least 10%, compared with 27% and 10% on placebo.

In people who already have type 2 diabetes, the numbers shrink. SCALE Diabetes, published in JAMA the same year, randomized 846 adults with type 2 diabetes and overweight or obesity. Mean weight loss at 56 weeks was 6.0% (about 6.4 kg) with the 3.0 mg strength versus 2.0% with placebo, with 54.3% reaching the 5% threshold. That attenuation in diabetes is a consistent finding across the whole GLP-1 class, not a liraglutide-specific weakness.

A third trial answered a different question: can liraglutide hold weight off? SCALE Maintenance enrolled adults who had already lost weight on a low-calorie diet. Over 56 weeks, 81.4% of the liraglutide group kept off at least 5% of their run-in weight loss versus 48.9% on placebo, and 50.5% lost a further 5% or more versus 21.8%. Maintenance, not just initial loss, is where most obesity interventions fail — so this result mattered.

Liraglutide is also the GLP-1 with the deepest adolescent evidence. The SCALE Teens trial randomized 251 participants aged 12 to under 18 with obesity and a poor response to lifestyle therapy. At 56 weeks, 43.3% of the liraglutide group achieved a BMI reduction of at least 5% versus 18.7% on placebo, with body weight about 4.5 kg lower. That trial is why the obesity indication was extended to adolescents.

An independent critical review of the liraglutide weight-management evidence reached a fair summary: real and reproducible effect, meaningful improvements in glycemic and cardiometabolic markers, but a high rate of gastrointestinal side effects and an effect size that requires continued treatment to persist.

Liraglutide trial results compared

Here is where liraglutide sits against the drugs that came after it. All figures are mean percentage change in body weight from the published primary analyses.

Cross-trial comparisons are imperfect — different populations, different lifestyle programs, different eras. STEP 8 is the exception, because it compared the two drugs directly in the same protocol.

Liraglutide vs semaglutide and tirzepatide

The STEP 8 randomized clinical trial, published in JAMA in 2022, is the cleanest answer available. It enrolled 338 adults with overweight or obesity but no diabetes across 19 US sites and ran for 68 weeks. Weekly semaglutide 2.4 mg reduced body weight by 15.8%. Daily liraglutide 3.0 mg reduced it by 6.4%. That is roughly a two-and-a-half-fold difference in the same trial, with the same lifestyle support, in the same patients.

The gap widens at the thresholds people actually care about. In STEP 8, far more participants on semaglutide crossed the 15% and 20% weight-loss marks — thresholds that liraglutide almost never reaches. On the diabetes side, a network meta-analysis of weekly semaglutide versus liraglutide found significantly greater HbA1c reduction with semaglutide, with treatment differences of roughly 0.3 to 0.5 percentage points against the higher liraglutide strengths.

Tirzepatide widened the gap further. SURMOUNT-1 reported mean weight reductions of up to 20.9% at 72 weeks with the dual GIP/GLP-1 agonist, and the later head-to-head trial of tirzepatide against semaglutide put tirzepatide ahead again. Read our full breakdowns of semaglutide, tirzepatide, and the direct tirzepatide vs semaglutide comparison if you want the detail.

Broader head-to-head evidence across the whole class is collected in this review of GLP-1 receptor agonist comparative studies, which places liraglutide above the older exenatide and lixisenatide but below the weekly agents on both glycemic and weight endpoints.

Why weekly GLP-1s pushed liraglutide aside

Three reasons, in order of importance.

Efficacy. A 6–8% average weight loss is clinically useful — it moves blood pressure, lipids, and glycemia — but patients and prescribers now have options that average twice that. Once STEP 8 published a direct comparison, the argument was largely over.

Injection burden. Liraglutide is 365 injections a year. Semaglutide is 52. Persistence data in real-world practice consistently favors weekly dosing, and a drug that gets abandoned at month four does not produce trial-level results.

Tolerability curve. Daily dosing means daily gastric slowing. Many patients find a weekly peak-and-trough easier to live with than continuous exposure, even though total gastrointestinal event rates are broadly comparable across the class.

What liraglutide retains is a fifteen-year safety record, a hard cardiovascular outcomes trial, a licensed pediatric indication, and — since 2024 — generic pricing. In markets where Wegovy and Ozempic are rationed, expensive, or out of stock, that combination still matters.

Liraglutide side effects reported in trials

The adverse event profile is the GLP-1 class profile, concentrated into a daily rhythm.

In SCALE Obesity and Prediabetes, the most common events with liraglutide were nausea, vomiting, diarrhea, constipation, dyspepsia, and headache. Most were mild to moderate and clustered in the first weeks after each dose escalation. Gastrointestinal complaints were also the leading reason for discontinuation.

The adolescent trial gives the sharpest numbers because the population was small and closely monitored: 64.8% of the liraglutide group reported gastrointestinal adverse events versus 36.5% on placebo, and 10.4% discontinued treatment because of adverse events versus none in the placebo arm.

Less common but clinically important signals reported across the SCALE program and post-marketing surveillance include gallbladder disease (cholelithiasis and cholecystitis, a known consequence of rapid weight loss), acute pancreatitis, elevated lipase and amylase, increased heart rate of a few beats per minute, and injection-site reactions. Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; whether this translates to human risk remains unresolved and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

One practical point that shows up in every trial protocol: the gastrointestinal events are dose-related and time-related. That is why the SCALE studies escalated the dose stepwise over several weeks rather than starting at target. How that is handled for any individual is a prescriber decision.

Does liraglutide protect the heart?

This is liraglutide's strongest remaining card. The LEADER trial randomized 9,340 people with type 2 diabetes at high cardiovascular risk to liraglutide or placebo and followed them for a median of 3.8 years. The primary composite outcome — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — occurred in 13.0% of the liraglutide group versus 14.9% of the placebo group. Cardiovascular death and all-cause mortality were both significantly reduced. Individual components including myocardial infarction, stroke, and heart failure hospitalization did not reach statistical significance on their own.

LEADER established that a GLP-1 agonist could do more than lower glucose and body weight. It reshaped diabetes treatment guidelines and set the template for the outcome trials that followed for semaglutide and, later, tirzepatide.

Is liraglutide FDA approved, and is it generic yet?

Approved, and yes.

Victoza received FDA approval for type 2 diabetes in 2010. Saxenda was approved for chronic weight management in December 2014, and the indication was later extended to adolescents aged 12 and older with obesity. Both are approved across the EU, UK, Canada, and Australia. Liraglutide is prescription-only everywhere it is licensed — it is not a supplement, not a research chemical, and not legal to sell for human use outside the prescription channel. If you are trying to work out where a given compound sits legally, see our overview of peptide legal status.

The commercial picture changed in 2024. Liraglutide became the first GLP-1 receptor agonist to lose exclusivity in the United States: generic versions for type 2 diabetes reached the market in 2024, and in August 2025 the FDA approved the first generic of the 3.0 mg weight-management formulation. That makes liraglutide the only pharmacy-grade GLP-1 currently available as a true generic — a meaningful consideration for anyone paying cash, and a preview of what will happen to semaglutide when its own patents lapse.

What happens when you stop liraglutide?

Weight comes back. This is the least popular fact about the entire class and the best documented.

In SCALE Teens, adolescents who stopped liraglutide regained more weight during the 26-week off-treatment follow-up than participants who had been on placebo. The same pattern appears with semaglutide: a dedicated withdrawal extension study found participants regained roughly two-thirds of their lost weight within a year of stopping, with cardiometabolic improvements reverting alongside.

The mechanistic reason is straightforward: GLP-1 agonists suppress appetite while present in the body. Liraglutide clears within days. Nothing about the underlying regulation of body weight has been permanently changed. Obesity pharmacotherapy has always behaved this way — the point is made in this review of obesity drug development — which is why regulators frame these drugs as chronic therapies rather than courses.

Tracking a daily GLP-1

Daily injectables are harder to keep straight than weekly ones. A weekly shot becomes a ritual. A daily shot blends into everything else, and by week six most people cannot recall which site they last used or when the nausea started tapering.

Three things are worth recording with any GLP-1: which days you injected, where, and what you felt in the 48 hours afterward. The third is the most useful at a follow-up appointment, because the pattern of gastrointestinal symptoms over time is exactly what a prescriber needs and exactly what memory distorts. For the wider class, see our guides to peptides used for weight loss, GLP-1 agonists, and keeping a usable log.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMed 26132939
2. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial — PubMed 26284720
3. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study — PubMed 23812094
4. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity — PubMed 32233338
5. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes — PubMed 27295427
6. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — PubMed 35015037
7. Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis — PubMed 34574899
8. Liraglutide for weight management: a critical review of the evidence — PubMed 28392927
9. Once-Weekly Semaglutide in Adults with Overweight or Obesity — PubMed 33567185
10. Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
11. Tirzepatide Once Weekly for the Treatment of Obesity — PubMed 35658024
12. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — PubMed 40353578
13. GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
14. The physiology of glucagon-like peptide 1 — PubMed 17928588
15. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435
16. Obesity pharmacotherapy: current perspectives and future directions — PubMed 23092275

Keep reading